Woodline Partners LP Has $21.62 Million Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR)

Woodline Partners LP boosted its holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 2.3% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 537,428 shares of the company's stock after acquiring an additional 12,334 shares during the period. Woodline Partners LP owned 0.83% of Kymera Therapeutics worth $21,621,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also added to or reduced their stakes in KYMR. Vident Advisory LLC acquired a new position in shares of Kymera Therapeutics in the fourth quarter valued at $236,000. State of Wyoming acquired a new stake in Kymera Therapeutics during the fourth quarter worth approximately $45,000. ProShare Advisors LLC boosted its holdings in shares of Kymera Therapeutics by 33.3% during the fourth quarter. ProShare Advisors LLC now owns 16,293 shares of the company's stock worth $655,000 after acquiring an additional 4,071 shares during the period. Nuveen Asset Management LLC grew its position in shares of Kymera Therapeutics by 2.2% in the fourth quarter. Nuveen Asset Management LLC now owns 143,225 shares of the company's stock valued at $5,762,000 after purchasing an additional 3,038 shares during the last quarter. Finally, Millennium Management LLC increased its position in Kymera Therapeutics by 205.0% during the 4th quarter. Millennium Management LLC now owns 115,918 shares of the company's stock worth $4,663,000 after buying an additional 77,912 shares during the period.

Analyst Upgrades and Downgrades

Several analysts have weighed in on KYMR shares. Citigroup began coverage on shares of Kymera Therapeutics in a research note on Thursday, March 13th. They issued a "buy" rating and a $52.00 price objective for the company. Stephens reissued an "overweight" rating and issued a $60.00 price objective on shares of Kymera Therapeutics in a research note on Tuesday, January 21st. Stifel Nicolaus began coverage on Kymera Therapeutics in a research note on Tuesday. They set a "buy" rating and a $55.00 target price for the company. Guggenheim reiterated a "buy" rating and issued a $52.00 price target on shares of Kymera Therapeutics in a research note on Monday, May 12th. Finally, UBS Group lowered their price target on Kymera Therapeutics from $72.00 to $70.00 and set a "buy" rating for the company in a report on Tuesday, May 13th. Four equities research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $55.25.

Kymera Therapeutics Stock Performance

Shares of NASDAQ KYMR opened at $31.44 on Wednesday. The firm has a 50 day moving average price of $29.23 and a two-hundred day moving average price of $36.76. The stock has a market cap of $2.05 billion, a P/E ratio of -13.44 and a beta of 2.18. Kymera Therapeutics, Inc. has a 52-week low of $19.45 and a 52-week high of $53.27.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last issued its quarterly earnings data on Friday, May 9th. The company reported ($0.82) earnings per share for the quarter, topping the consensus estimate of ($0.92) by $0.10. The company had revenue of $22.10 million for the quarter, compared to analysts' expectations of $11.38 million. Kymera Therapeutics had a negative net margin of 191.26% and a negative return on equity of 24.96%. Kymera Therapeutics's revenue for the quarter was up 114.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.69) earnings per share. Analysts predict that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current fiscal year.

Insider Buying and Selling at Kymera Therapeutics

In other Kymera Therapeutics news, CFO Bruce N. Jacobs sold 7,035 shares of the company's stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $30.45, for a total transaction of $214,215.75. Following the sale, the chief financial officer now owns 201,886 shares of the company's stock, valued at approximately $6,147,428.70. This represents a 3.37% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, COO Jeremy G. Chadwick sold 1,383 shares of the stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $30.45, for a total value of $42,112.35. Following the sale, the chief operating officer now owns 67,800 shares of the company's stock, valued at approximately $2,064,510. The trade was a 2.00% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 10,659 shares of company stock worth $324,567. Insiders own 16.01% of the company's stock.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.